CADL vs. NUVB, AVXL, CDMO, RLAY, TYRA, QURE, ORIC, SANA, CRMD, and CRON
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), Avid Bioservices (CDMO), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), uniQure (QURE), ORIC Pharmaceuticals (ORIC), Sana Biotechnology (SANA), CorMedix (CRMD), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs.
Nuvation Bio (NYSE:NUVB) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.
In the previous week, Nuvation Bio had 11 more articles in the media than Candel Therapeutics. MarketBeat recorded 12 mentions for Nuvation Bio and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.87 beat Nuvation Bio's score of 0.14 indicating that Candel Therapeutics is being referred to more favorably in the news media.
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Nuvation Bio currently has a consensus price target of $8.20, indicating a potential upside of 242.38%. Candel Therapeutics has a consensus price target of $19.00, indicating a potential upside of 172.99%. Given Nuvation Bio's higher probable upside, research analysts plainly believe Nuvation Bio is more favorable than Candel Therapeutics.
Nuvation Bio's return on equity of -21.89% beat Candel Therapeutics' return on equity.
Nuvation Bio has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -1.2, meaning that its share price is 220% less volatile than the S&P 500.
Candel Therapeutics has higher revenue and earnings than Nuvation Bio. Candel Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Nuvation Bio received 38 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Nuvation Bio an outperform vote while only 55.56% of users gave Candel Therapeutics an outperform vote.
Summary
Nuvation Bio beats Candel Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 1/30/2025 by MarketBeat.com Staff
